40% of Ozempic Weight Loss Isn't Fat. Here's the Fix.

A patient walked into my clinic last month looking like a completely different person. She had lost 18 kg on Wegovy over 14 months. She was thrilled. Her clothes fit. Her knees stopped hurting. Her blood sugar was the best it had been in a decade.

Then we scanned her.

Her body fat had dropped nicely. But her lean mass, the muscle that keeps you strong, mobile, and metabolically healthy, was down almost 7 kg. Her grip strength had quietly declined. She was thinner, yes. But she was also, on paper, more frail than when she started.

She had no idea. And to be fair to her doctor, nobody had really told her this was possible.

If you or someone you love is on Ozempic, Wegovy, Mounjaro or Zepbound, this is the conversation you need to have. Because these drugs are remarkable. The weight loss is real. The cardiovascular benefits are real. But there is a trade-off, and it's one nobody wants to talk about at the hype-filled end of the clinic visit.

Roughly 25% to 40% of the weight you lose on a GLP-1 medication is not fat. It is muscle. And from a longevity standpoint, that matters enormously.

The Medications Everyone Is Talking About

Let's quickly set the scene. Semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (sold as Mounjaro and Zepbound) are GLP-1 receptor agonists. They mimic a gut hormone that tells your brain you're full, slows gastric emptying, and improves insulin response.

The weight loss data is genuinely impressive. In the STEP 1 trial, published in the New England Journal of Medicine in 2021, participants on semaglutide 2.4 mg lost about 14.9% of their body weight over 68 weeks, compared to 2.4% on placebo. The newer STEP UP trial, published in The Lancet Diabetes & Endocrinology in 2025, tested a higher dose (semaglutide 7.2 mg) and found mean weight loss of around 18.7% over 72 weeks, with adherent patients losing more than 20%.

These are weight loss numbers that used to require bariatric surgery. And the cardiovascular benefits matter too. The SELECT trial showed that semaglutide reduced major adverse cardiovascular events by 20% in adults with established heart disease and obesity, which is why Wegovy now carries that indication in Singapore and elsewhere.

I am not anti-GLP-1. I prescribe these medications. For the right patient, they can be transformative.

But "transformative" and "no trade-offs" are not the same thing. And the trade-off that gets swept under the rug is the one happening in your muscle.

What the Body Composition Data Actually Shows

When you lose weight from any cause, some of it is muscle. That's true for dieting, bariatric surgery, illness, or ageing. The question is how much.

In the STEP 1 DXA substudy, published in Obesity in 2021, 140 participants had their body composition measured before and after treatment. In the semaglutide group, total fat mass dropped by about 8.4 kg, and total lean body mass dropped by about 5.3 kg. That's almost 40% of the weight loss coming from lean tissue.

A comprehensive 2024 review in Diabetes, Obesity and Metabolism by Neeland and colleagues summarised data across multiple GLP-1 trials and confirmed that lean soft tissue loss typically accounts for 25% to 40% of total weight lost.

To put that in perspective: if you lose 20 kg on a GLP-1, you may be losing 5 to 8 kg of muscle along with the fat. That's a lot.

Now, the drug's defenders will point out, accurately, that the proportion of lean mass relative to total body mass often goes up. Fat loss is bigger than muscle loss, so on paper your body composition improves. That's true. But if your muscle mass was already borderline, or if you are over 50, or if you are a woman (who typically starts with less muscle to begin with), that absolute loss of kilograms of muscle is a longevity problem, not a longevity win.

Why Your Muscle Is Your Longevity Insurance

Muscle is not just for looking toned. It's one of the most important organs you have, and most people don't think of it that way.

Your muscle is where you store and dispose of glucose. It's the biggest determinant of your resting metabolic rate. It protects your bones. It catches you when you trip. It lets you carry your grandchild. It is the single strongest predictor of all-cause mortality in adults over 50.

The Prospective Urban Rural Epidemiology (PURE) study, which followed more than 139,000 adults across 17 countries, found that grip strength, a crude but reliable marker of total body muscle strength, predicted cardiovascular death and all-cause mortality more strongly than systolic blood pressure.

Sarcopenia, the age-related loss of muscle mass and function, is one of the strongest drivers of frailty, falls, fractures, hospitalisation, and loss of independence in older adults. And once you hit your 40s, you are losing around 3% to 8% of your muscle per decade anyway. Add a GLP-1 on top, without a plan, and you're accelerating that clock.

So yes, the weight comes off. But if the engine that keeps you strong for the next 30 years comes off with it, you have traded one problem for another.

The Circulation Paper: Is Muscle Loss Adaptive or Maladaptive?

There's a nuance I want to be honest about. In 2024, Conte and colleagues published a thoughtful commentary in Circulation arguing that some of the lean mass loss on GLP-1s is probably "adaptive." When you lose 20% of your body weight, you don't need as much muscle to carry that weight around. Your muscle is also less infiltrated with fat, your muscle quality improves, and insulin sensitivity goes up.

That's a fair point. Not every kilogram of lean mass loss is bad.

But "adaptive" doesn't mean "safe for everyone." The authors themselves flagged that older adults, women, people with pre-existing sarcopenia, and anyone who is already frail are at real risk of crossing from "healthy right-sizing" into genuine muscle inadequacy. And we can't reliably tell, from the outside, which camp you're in without measuring it.

That's exactly why body composition testing should, in my view, be part of any serious GLP-1 prescription plan. You need a starting line. Otherwise you are shooting in the dark.

The Singapore Context

Obesity in Singapore is quietly climbing. The National Population Health Survey 2024 reported that obesity prevalence among adults had risen from 10.5% in 2019–2020 to 12.7% in 2023–2024. Singapore's Health Sciences Authority approved Wegovy for weight management in March 2023, and in the years since, GLP-1 prescribing has expanded rapidly across public and private clinics.

In my practice, I've seen a steady rise in patients arriving already on a GLP-1, often started by a telehealth service or overseas prescriber, with very little structured guidance on nutrition, protein intake, or exercise. The focus is almost always on the scale number. Rarely on what's happening underneath.

This matters even more in an Asian population. Asians, including Singaporeans, tend to carry more visceral fat and less skeletal muscle at any given BMI than Caucasians. We get metabolic disease at lower BMIs. And we have less muscle reserve to start with. Losing kilograms of muscle unchecked, on top of that baseline, is not something to shrug off.

The Protocol: How to Use a GLP-1 Without Wrecking Your Muscle

Here's the good news. The muscle loss on GLP-1s is not inevitable. It responds to intervention. Several 2025 studies have now shown that with the right plan, you can dramatically shift the ratio of fat loss to muscle loss.

In a 6-month prospective study presented at ENDO 2025 by researchers from the Washington University School of Medicine, 200 adults on semaglutide or tirzepatide who received structured education on resistance training and higher protein intake lost about 13% of body weight, but only about 3% of muscle mass. Compare that to the 25% to 40% muscle loss seen in unsupported patients, and the effect is striking.

Here's what actually works, based on the strongest evidence available.

1. Eat Enough Protein. More Than You Think.

The appetite-suppressing effect of GLP-1s is powerful. Many patients drop from three meals to one, lose interest in meat, and start living on a single piece of toast and a cup of coffee. That's a recipe for muscle wasting.

Aim for at least 1.2 to 1.6 g of protein per kg of body weight per day while on a GLP-1, ideally distributed across three meals. For a 70 kg adult, that's roughly 84 to 112 g of protein daily. Good sources in Singapore include fish (salmon, mackerel, threadfin), chicken breast, eggs, tofu, tempeh, Greek yogurt, cottage cheese, and legumes. A scoop of whey protein in the morning can make this target realistic when appetite is suppressed.

The Endocrine Society's 2025 clinical presentations emphasised this point: protein intake, not just total calories, is what predicts muscle preservation on GLP-1 therapy.

2. Lift Heavy Things. Two to Three Times a Week.

Resistance training is non-negotiable. Cardio is fine, but it does not preserve muscle the way lifting does. The 2025 STEP UP substudy presented at EASD showed that exercise benefits for lean mass preservation were even more pronounced in older participants, with participants over 65 who exercised retaining a significantly higher proportion of lean mass than their sedentary peers.

Two to three sessions per week of proper resistance training, working all major muscle groups, is the sweet spot for most adults. That can be a gym program with a trainer, a home dumbbell routine, or even bodyweight work if you're starting out. What matters is progression: the weights or reps have to go up over time, otherwise you are not challenging the muscle enough to keep it.

If you've never lifted before, get a session with a qualified trainer to learn the basic movements: squat, hinge (deadlift), push (bench or overhead press), pull (row), and carry. Those five patterns cover the majority of what keeps you functional for the rest of your life.

3. Measure, Don't Guess.

If you are on a GLP-1 or thinking about starting one, get a body composition scan at baseline and every three to six months. A DXA scan is the gold standard. It tells you exactly how much lean and fat tissue you have, segment by segment.

I've had patients whose weight dropped 8 kg in four months who, on DXA, showed 6 kg of fat loss and 2 kg of muscle loss. That's a good outcome. I've had others drop the same 8 kg where 4 kg was muscle. That's a warning sign, and it changes the plan immediately.

You can't manage what you don't measure. And "I feel fine" is not a reliable measure of muscle health. Neither is the scale.

4. Don't Stop Suddenly Without a Plan.

When people come off GLP-1s without a weight-maintenance plan, a large chunk of the weight comes back, and often the regain is disproportionately fat, not muscle. You lose muscle on the way down and regain fat on the way up. Over a few cycles, that body composition shift is harmful.

If you are planning to taper or stop, build the nutrition and resistance training habits before you stop, not after. Your muscle needs stimulus and protein to hold onto its size through the transition.

5. Go Slow on the Dose.

Higher doses and faster titration generally produce more appetite suppression, which can push protein intake dangerously low. For many patients, a lower effective dose with excellent nutrition and training habits produces a better body composition outcome than the maximum dose with poor habits.

This is a conversation to have with your prescribing doctor, not a reason to self-adjust. But don't assume that "more" is always "better."

A Real Case: Same Drug, Two Very Different Bodies

Two of my patients, both started on semaglutide around the same time, illustrate this perfectly.

Patient A is a 52-year-old executive. He took the prescription home, cut his meals in half, ate mostly carbs because protein made him nauseous, and told himself he'd start exercising "when things stabilised." After 10 months he'd lost 14 kg. On DXA, about 6 kg of that was lean mass. His grip strength had fallen. His biological age, measured by DNA methylation, was roughly unchanged from before the drug. He looked smaller, but his longevity trajectory had barely improved.

Patient B is a 54-year-old teacher. Same drug, same dose. But she came in for a body composition scan before starting, worked with a dietitian to hit 1.4 g/kg of protein, and trained twice a week with a personal trainer. After 10 months she'd lost 13 kg, of which only 1.5 kg was lean mass. Her grip strength actually improved. Her biological age dropped by about three years on follow-up testing. Same medication. Radically different result.

The drug didn't make the difference. The protocol around the drug did.

The Bigger Point

GLP-1 medications are one of the most powerful tools we have for obesity. Used well, they can meaningfully reduce cardiovascular risk, reverse fatty liver, and restore metabolic health in people who've struggled with weight for decades. I'm glad they exist.

But the reason people started losing weight in the first place, for most of my patients, was to live longer and healthier, not just to wear smaller clothes. And if the weight loss comes at the cost of the very tissue that predicts how well you'll age, you are solving one problem by creating another.

The fix isn't to avoid the drug. The fix is to pair it with a grown-up plan. Enough protein. Real resistance training. Measurement. Follow-up.

If you're considering starting a GLP-1, or you're already on one, do yourself a favour: get a DXA body composition scan, talk to your doctor about a protein and exercise target, and measure again in three to six months. That simple loop is the difference between getting smaller and getting healthier.

Because the goal was never just to weigh less. The goal was to live better, for longer. And the muscle you keep today is the independence you still have at 85.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
2. Wilding JPH, Batterham RL, Davies M, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society. 2021;5(Supplement_1):A16-A17. Published as Obesity body composition substudy. DOI: 10.1210/jendso/bvab048.030
3. Kushner RF, Calanna S, Davies M, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology. 2025. DOI: 10.1016/S2213-8587(25)00226-8
4. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. 2024;26(Suppl 4):16-27. DOI: 10.1111/dom.15728
5. Conte C, Hall KD, Klein S. Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Circulation. 2024;150(16):1307-1310. DOI: 10.1161/CIRCULATIONAHA.124.067676
6. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232. DOI: 10.1056/NEJMoa2307563
7. Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. The Lancet. 2015;386(9990):266-273. DOI: 10.1016/S0140-6736(14)62000-6
8. Ministry of Health Singapore. National Population Health Survey 2024. Singapore: MOH; 2024. URL: moh.gov.sg
9. Haines M, et al. Resistance Training and Higher Protein Intake May Reduce Muscle Loss in Patients on GLP-1 Receptor Agonists. Presented at ENDO 2025, Endocrine Society Annual Meeting. URL: endocrine.org
10. Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. The Lancet Diabetes & Endocrinology. 2024;12(11):785-787. DOI: 10.1016/S2213-8587(24)00272-9